OS Animal Health, a wholly owned subsidiary of OS Therapies Inc. (NYSE American: OSTX), was featured in coverage of the Disruptive Growth & Life Sciences Conference hosted by Moody Capital Solutions. The company is dedicated to improving outcomes for pets with cancer and is making strides in developing OST-HER2, an immunotherapy designed to treat canine osteosarcoma, a common and aggressive bone cancer in dogs.
OST-HER2 is being positioned as a potential “go-to” option for all HER2 positive cancers in dogs and eventually for other companion animals. The company is working to re-establish U.S. Department of Agriculture (USDA) conditional approval to bring this innovative treatment to the veterinary oncology market. This effort is significant because current treatment options for canine osteosarcoma are limited, often involving amputation and chemotherapy, which have poor long-term survival rates.
The conference, organized by Moody Capital Solutions, an independent investment bank with over 40 years of experience in capital raising and advisory services, provided a platform for emerging life sciences companies to present their latest developments. OS Animal Health’s participation highlights the growing interest in veterinary oncology, a niche but rapidly expanding field within animal health.
The importance of this announcement lies in the potential of OST-HER2 to fill an unmet medical need in veterinary medicine. If approved, it could offer a targeted, less invasive treatment option for dogs suffering from HER2 positive cancers, potentially improving quality of life and survival outcomes. Moreover, the success of such a therapy could pave the way for similar immunotherapies in other companion animals, expanding the scope of personalized medicine beyond human healthcare.
OS Therapies, the parent company, is focused on developing immunotherapies for both human and animal cancers. The company’s expertise in HER2-targeted therapy, originally developed for human cancers, is being adapted for veterinary use, demonstrating cross-species translational research. This approach not only benefits pets but also provides valuable data that could inform human clinical trials.
Investors and stakeholders are closely watching the progress of OST-HER2 as it navigates the regulatory pathway. The conference coverage by IBN, a multifaceted financial news and publishing company, aims to increase visibility for OS Animal Health and other participating companies. IBN’s portal provides summaries and access to market research tools, helping investors evaluate these emerging opportunities.
Moody Capital Solutions’ conference serves as a catalyst for connecting innovative companies with potential investors and partners. OS Animal Health’s presence at this event underscores its commitment to advancing veterinary oncology and its confidence in the potential of OST-HER2.
For more information on OS Therapies and its veterinary oncology programs, visit the company’s website at https://ostherapies.com/. To learn more about the conference and its participants, visit https://moodycapital.com/conference/. IBN’s coverage of the event can be accessed at https://ibn.fm/MoodyCapital2026Conference.
The development of OST-HER2 represents a significant step forward in the fight against cancer in pets, offering hope to dog owners and veterinarians alike. As the company works toward regulatory approval, the outcomes of this effort could have lasting implications for the field of veterinary oncology and beyond.
